Long-term AICAR administration and exercise prevents diabetes in ZDF rats.

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35

AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 2.44

AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 2.40

Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem (2010) 2.19

AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) (2009) 2.13

AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J (2009) 2.09

Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes (2010) 1.64

Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed) (2009) 1.51

Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol (2011) 1.41

Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL. J Lipid Res (2008) 1.38

Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes (2008) 1.25

AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation. Nat Med (2012) 1.19

Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators. IUBMB Life (2009) 1.14

Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes (2013) 1.12

Impaired skeletal muscle beta-adrenergic activation and lipolysis are associated with whole-body insulin resistance in rats bred for low intrinsic exercise capacity. Endocrinology (2009) 1.09

Endurance factors improve hippocampal neurogenesis and spatial memory in mice. Learn Mem (2011) 1.07

Energy disruptors: rising stars in anticancer therapy? Oncogenesis (2016) 1.02

Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance. Diabetes (2010) 1.00

AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol (2011) 0.99

Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp Diabetes Res (2011) 0.98

Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. J Cereb Blood Flow Metab (2010) 0.93

Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J Appl Physiol (1985) (2010) 0.93

A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis. ACS Med Chem Lett (2010) 0.89

The full capacity of AICAR to reduce obesity-induced inflammation and insulin resistance requires myeloid SIRT1. PLoS One (2012) 0.87

Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol (2014) 0.86

Chronic treatment with the AMP-kinase activator AICAR increases glycogen storage and fatty acid oxidation in skeletal muscles but does not reduce hyperglucagonemia and hyperglycemia in insulin deficient rats. PLoS One (2013) 0.85

Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus. Mediators Inflamm (2011) 0.84

Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance. Future Med Chem (2010) 0.82

AICAR administration ameliorates hypertension and angiogenic imbalance in a model of preeclampsia in the rat. Am J Physiol Heart Circ Physiol (2013) 0.81

Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus - correlation with pancreatic β-cell function. Diabetol Metab Syndr (2014) 0.80

Can patients with type 2 diabetes be treated with 5'-AMP-activated protein kinase activators? Diabetologia (2008) 0.80

Caffeamide 36-13 Regulates the Antidiabetic and Hypolipidemic Signs of High-Fat-Fed Mice on Glucose Transporter 4, AMPK Phosphorylation, and Regulated Hepatic Glucose Production. Evid Based Complement Alternat Med (2014) 0.79

Chicoric acid is an antioxidant molecule that stimulates AMP kinase pathway in L6 myotubes and extends lifespan in Caenorhabditis elegans. PLoS One (2013) 0.79

Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase. J Virol (2016) 0.79

AICAR positively regulate glycogen synthase activity and LDL receptor expression through Raf-1/MEK/p42/44MAPK/p90RSK/GSK-3 signaling cascade. Biochem Pharmacol (2007) 0.78

The time has come to test the beta cell preserving effects of exercise in patients with new onset type 1 diabetes. Diabetologia (2014) 0.77

Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. PLoS One (2015) 0.77

Thioredoxin-mimetic peptide CB3 lowers MAPKinase activity in the Zucker rat brain. Redox Biol (2014) 0.77

Exercise training prevents decrease in luminal capillary diameter of skeletal muscles in rats with type 2 diabetes. ScientificWorldJournal (2012) 0.76

A 6-week training program increased muscle antioxidant system in elderly diabetic fatty rats. Med Sci Monit (2012) 0.76

Energy dense, protein restricted diet increases adiposity and perturbs metabolism in young, genetically lean pigs. PLoS One (2013) 0.76

Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects. Diabetes Metab Syndr Obes (2013) 0.75

What we have learnt about PIKE from the knockout mice. Int J Biochem Mol Biol (2011) 0.75

Reconstruction of Purine Metabolism in Bacillus subtilis to Obtain the Strain Producer of AICAR: A New Drug with a Wide Range of Therapeutic Applications. Acta Naturae (2011) 0.75

Loss of the anorexic response to systemic 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside administration despite reducing hypothalamic AMP-activated protein kinase phosphorylation in insulin-deficient rats. PLoS One (2013) 0.75

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 21.91

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44

Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell (2008) 4.92

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14

Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59

Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest (2012) 3.33

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27

Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes (2007) 3.25

Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes (2002) 3.21

Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science (2014) 3.14

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87

Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81

Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes (2004) 2.74

Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest (2002) 2.65

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64

Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42

Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39

Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) (2009) 2.32

AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. J Biol Chem (2006) 2.24

Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes (2006) 2.24

Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. J Biol Chem (2008) 2.09

Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol (2006) 2.09

Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem (2003) 2.07

Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes (2007) 1.98

Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol (1985) (2007) 1.83

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab (2002) 1.83

Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes (2012) 1.82

AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab (2006) 1.80

Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am J Physiol Endocrinol Metab (2007) 1.77

Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem (2002) 1.76

Contraction regulation of Akt in rat skeletal muscle. J Biol Chem (2002) 1.76

AMP-activated protein kinase alpha2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle. J Biol Chem (2005) 1.76

A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun (2008) 1.75

From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74

Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol (2004) 1.73

Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71

Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69

Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes (2002) 1.68

Contraction signaling to glucose transport in skeletal muscle. J Appl Physiol (1985) (2005) 1.67

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes (2007) 1.64

Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63

Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61

Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61

Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60

Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes (2008) 1.59

Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59

Invited review: intracellular signaling in contracting skeletal muscle. J Appl Physiol (1985) (2002) 1.58

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 1.56

TBC1D1 regulates insulin- and contraction-induced glucose transport in mouse skeletal muscle. Diabetes (2010) 1.55

Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes (2008) 1.55

Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET. Eur J Nucl Med Mol Imaging (2006) 1.53

The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52

Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49

Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle. Proc Natl Acad Sci U S A (2010) 1.48

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes (2002) 1.46

Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology (2012) 1.44

Signaling mechanisms in skeletal muscle: acute responses and chronic adaptations to exercise. IUBMB Life (2008) 1.41

Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest (2007) 1.40

Stretch-stimulated glucose uptake in skeletal muscle is mediated by reactive oxygen species and p38 MAP-kinase. J Physiol (2009) 1.40

p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol Cell Biol (2004) 1.39

[Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications]. Ugeskr Laeger (2003) 1.39

Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care (2002) 1.38

Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials (2006) 1.38

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37

5'-AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle. J Appl Physiol (1985) (2002) 1.37

Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol (2009) 1.36

Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care (2005) 1.35

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One (2013) 1.34

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol (2006) 1.34

Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev (2013) 1.34

Beta-cell secretory dysfunction in the pathogenesis of low birth weight-associated diabetes: a murine model. Diabetes (2005) 1.33

Adrenaline is a critical mediator of acute exercise-induced AMP-activated protein kinase activation in adipocytes. Biochem J (2007) 1.31

Effects of exercise training on subcutaneous and visceral adipose tissue in normal- and high-fat diet-fed rats. Am J Physiol Endocrinol Metab (2009) 1.31

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab (2006) 1.31